VJHemOnc is committed to improving our service to you

EBMT-EHA CAR-T 2019 | The future of treating pediatric patients with hematological malignancies

VJHemOnc is committed to improving our service to you

Claudia Rössig

Claudia Rössig, MD, of the University of Münster, Münster, Germany discusses the future for CAR T-cell therapy in pediatrics. In pediatrics, CAR T-cel therapy has reached a high cure rate in the acute lymphoblastic leukemia (ALL) indication. However, Dr Rössig explains that there is now a challenge to improve this further and reduce toxicities. There is a hope for CAR T-cell therapy to act as a standalone therapy for children with ALL, replacing toxic components of chemotherapy and stem cell transplantation, and have better long term outcomes. Recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter